BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Cellceutix 

100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


SEARCH JOBS










 Company News
Cellceutix (CTIX) Reports Positive Results Of Brilacidin In Microbiological Intent-To-Treat Population In Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information To Be Submitted 12/23/2014 9:37:59 AM
Cellceutix (CTIX): Prurisol™ For Psoriasis -- FDA Agrees That Phase 2 Study May Begin 12/11/2014 8:15:26 AM
Cellceutix (CTIX) Antibiotic Brilacidin Receives QIDP Designation From FDA 12/10/2014 11:40:05 AM
Patient Enrollment In Cellceutix (CTIX) Phase 2 Clinical Trial Of Brilacidin-OM For Oral Mucositis Targeted To Begin In December 2014 11/11/2014 10:54:43 AM
Cellceutix (CTIX)'s New Chief Operating Officer Dr. James Alexander Addresses Shareholders 11/3/2014 1:31:55 PM
Cellceutix (CTIX) Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable To 7-Days Of Daptomycin 10/23/2014 10:47:29 AM
Cellceutix (CTIX) Investigational New Drug (IND) Application Becomes Effective, Selects First Site For Phase 2 Clinical Trial Of New Treatment For Oral Mucositis 10/13/2014 10:55:18 AM
Cellceutix (CTIX) Provides Update To Shareholders 9/26/2014 2:45:17 PM
Cellceutix (CTIX) To President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat To Public Health 9/22/2014 1:39:29 PM
Cellceutix (CTIX) Provides Initial Observations Of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application To FDA For Phase 2 Trial Of Brilacidin-OM For Oral Mucositis 9/10/2014 11:31:01 AM
12345678910...